Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886901 | 0.86 | MEN1 (0.49) | SLC6A3MEN1KMT2ATDP1KDM4C | |
| SCHEMBL9860360 | 0.85 | MEN1 (0.54) | SLC6A3MEN1KMT2ATDP1KDM4C | |
| SCHEMBL22504269 | 0.84 | KMT2A (0.52) | SLC6A3MEN1KMT2ATDP1KDM4C | |
| SCHEMBL21326182 | 0.84 | CHRM2 (0.43) | SLC6A3MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL21374326 | 0.83 | MEN1 (0.49) | SLC6A3MEN1KMT2ATDP1KDM4C | |
| SCHEMBL8486775 | 0.81 | SLC6A3 (0.60) | SLC6A3MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL17846111 | 0.78 | MEN1 (0.48) | SLC6A3MEN1KMT2ATDP1KDM4C | |
| SCHEMBL5725637 | 0.78 | MEN1 (0.50) | SLC6A3MEN1KMT2ATDP1KDM4C | |
| SCHEMBL22494465 | 0.78 | MEN1 (0.43) | SLC6A3MEN1KMT2AADORA3 | |
| SCHEMBL9306096 | 0.77 | MEN1 (0.47) | SLC6A3MEN1KMT2AKDM4CADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604517-B2 | Bridged piperidine derivatives | HPGDS, APP, PSEN1 | SLC6A3 1395/4885MEN1 2472/4885KMT2A 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.